The first major study validating the effects of SGLT2 inhibitors was the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) Outcome Trial [85]. Here, SLC5A2 is linked to type 2 diabetes mellitus.